IgM ( 
consisted of a scale ranging from normal power (0) to no active movement (4) used on six different muscle groups; a corresponding scale for cranial nerve involvement ranged from 0 to 3. The muscle weakness score was calculated as the sum of the seven muscle groups tested. Thus, the range was from 0 (normal motor function) to 27 (total paralysis in all muscles examined). (fig 3) ).
Results
Patient No 1 had a polyneuropathy initially 
function in the feet.'8 After eight months, however, a slow deterioration again started, now also involving the hands, and therefore a new series of plasma exchange was performed. After six treatments during two weeks, the interval between treatments was gradually increased to one week, two weeks, and finally one month. IgM and antibodies to PNM decreased during the intensive treatment period, as in the previous study,"8 and remained at a low level during the period with weekly plasma exchange but increased when the interval was two weeks or longer (data not shown). The patient did not improve, and chlgrambucil 6 mg/day was started (fig 1) .
Prednisolone was added for a time, but clinical deterioration continued; therefore a new series of plasma exchange (six treatments during two weeks, and then once weekly for five weeks) was performed during continuous chlorambucil treatment. The patient's clinical status then stabilised, and after six months a clear improvement was noted (fig 1) There was a delay of two to six months between the treatment period and clinical improvement in two patients with lowered antibodies to PNM. Considering that there is established demyelination in the peripheral nerves, it is reasonable to expect a delay until improvement is noted, and this should be taken into account when deciding the length of a treatment period.
Previous experience in treating monoclonal IgM neuropathies is summarised in 
